Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
5-(3-(2,6-dichloro-4-(4,5-dihydro-2-oxazolyl)phenoxy)propyl)-3-methyl isoxazole
- Development stage
- Unknown
- Modality
- Small Molecules
01
Overview
5-(3-(2,6-dichloro-4-(4,5-dihydro–2–oxazolyl)phenoxy)propyl)-3-methyl isoxazole (also known as Win 56291 or Win–56291), is a synthetic small molecule belonging to the phenol ether class. It features an aromatic ether group substituted with a benzene ring and contains both dichlorophenoxy and oxazoline moieties. The compound has been identified in chemical databases as an experimental agent with no approved medical indications or clinical trial activity. Its only reported biological target is the "genome polyprotein," suggesting it may have been investigated for antiviral properties or as a molecular probe in virology research; however, there are no published data on its mechanism of action in humans or animals[1][2][5]. No developer or manufacturer information exists for this compound.
- Other names
- 5-(3-(2,6-dichloro-4-(4,5-dihydro-2-oxazolyl)phenoxy)propyl)-3-methyl isoxazole5-{3-[2,6-dichloro-4-(4,5-dihydro-1,3-oxazol-2-yl)phenoxy]propyl}-3-methylisoxazoleTVM6INF0BBTVM-6INF0BBTVM 6INF0BBCHEMBL143305CHEMBL-143305CHEMBL 143305DTXSID90148021DTXSID-90148021DTXSID 90148021DB08728DB-08728DB 08728KEGG C06499
Beyond the preview
Go deeper on 5-(3-(2,6-dichloro-4-(4,5-dihydro-2-oxazolyl)phenoxy)propyl)-3-methyl isoxazole.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 5-(3-(2,6-dichloro-4-(4,5-dihydro-2-oxazolyl)phenoxy)propyl)-3-methyl isoxazole.